Does T3 support hepatic LDL receptor expression and LDL clearance?

Triiodothyronine (T3) is a primary physiological regulator of hepatic lipid metabolism, directly modulating the clearance of atherogenic lipoproteins from circulation.

Mechanistic pathways of LDL receptor upregulation

• Direct genomic activation: T3 acts as a direct ligand for thyroid hormone receptor beta-1 (TRβ1), the dominant receptor isoform in the liver. The T3-TRβ1 complex binds directly to thyroid hormone response elements (TREs) on the hepatic low-density lipoprotein receptor (LDLR) promoter (specifically the US-TRE site around −612 bp). This process rapidly initiates LDLR gene transcription within 30 to 60 minutes.
• Indirect transcriptional amplification: Over longer intervals, T3 upregulates the expression and transcriptional activity of sterol regulatory element-binding protein 2 (SREBP-2). SREBP-2 binds to sterol regulatory elements (SREs) on the LDLR promoter, providing sustained, additive receptor expression on the hepatocyte membrane.

Consequences of low free T3 on lipid profiles

• Impaired clearance: Insufficient free T3—resulting from hypothyroidism, non-thyroidal illness, or relative T3 deficiency during levothyroxine monotherapy—reduces hepatic LDLR density and diminishes receptor-mediated LDL clearance.
• Atherogenic accumulation: Because each low-density lipoprotein particle contains a single apolipoprotein B-100 (ApoB-100) structural molecule, a lower clearance rate directly increases circulating LDL cholesterol (LDL-C), ApoB concentrations, and total LDL particle number (LDL-P).

Bottom line

• Adequate free T3 is biologically necessary to maintain hepatic LDLR expression. Low free T3 levels impair receptor-mediated clearance, directly driving elevations in circulating LDL-C, ApoB, and LDL-P, which promotes an atherogenic lipid profile.